loading page

Circulating tumour DNA as a complementary tool for treatment evaluation in HPV-associated Head and neck squamous cell carcinoma: An observational cohort study
  • +4
  • Anna Oldaeus Almerén,
  • Max Waenerlund,
  • Fredrik Landström,
  • Mathias Beckerath,
  • Alvida Qvick,
  • Jessica Carlsson,
  • Gisela Helenius
Anna Oldaeus Almerén
Region Orebro lan

Corresponding Author:[email protected]

Author Profile
Max Waenerlund
Orebro universitet Fakulteten for medicin och halsa
Author Profile
Fredrik Landström
Region Orebro lan
Author Profile
Mathias Beckerath
Orebro universitet Fakulteten for medicin och halsa
Author Profile
Alvida Qvick
Universitetssjukhuset Orebro Laboratoriemedicinska kliniken
Author Profile
Jessica Carlsson
Orebro universitet Fakulteten for medicin och halsa
Author Profile
Gisela Helenius
Orebro universitet Fakulteten for medicin och halsa
Author Profile

Abstract

Objectives HPV-positive Oropharyngeal squamous cell carcinoma (OPSCC) and Head and neck carcinoma of unknown primary (HNCUP) is increasing. Despite good prognosis, recurrence rates range from 10- to 25%. Surveillance with clinical controls and imaging are not always reliable. Circulating tumour human papillomavirus DNA (ctHPV-DNA) has emerged as a potential biomarker for treatment evaluation and detection of recurrence. We aimed to investigate the correlation between ctHPV-DNA in HPV+ OPSCC/HNCUP and radiologic tumour burden. Additionally, we sought to assess whether ctHPV-DNA could serve as a tool in treatment evaluation. Design A prospective observational cohort study. Setting This multicenter study involved three otolaryngology units located in central Sweden. We utilised HPV genotype-specific assays for droplet digital PCR (ddPCR) to detect ctHPV-DNA in plasma at diagnosis and follow-up. ctHPV-DNA levels were correlated to radiological tumour burden and radiological response using Kendall Rank correlation coefficient and Kruskal Wallis test. Participants Patients with HPV+ OPSCC/HNCUP undergoing definitive (chemo)radiotherapy. Results Out of 54 patients, 51 were eligible for analyses. At baseline, ctHPV-DNA was detectable in 88%. The majority of patients with a favourable radiological evaluation according to RECIST, had a corresponding undetectable ctHPV-DNA at follow-up. The levels of ctHPV-DNA at baseline correlated with Total Tumour Volume and Nodal Volume (r τ = 0.39, p<0.01, respectively r τ =0.26, p<0.01). Conclusion ctHPV-DNA shows correlation with tumour burden. This study strengthens the role of ctHPV-DNA as a promising biomarker for diagnosing and monitoring HPV-related OPC/HNCUP. With further research on serial plasma sampling, ctHPV-DNA could complement radiological treatment evaluation in HPV+ OPSCC/HNCUP.
Submitted to Clinical Otolaryngology
27 Jul 2024Review(s) Completed, Editorial Evaluation Pending
23 Aug 2024Editorial Decision: Revise Minor
08 Sep 20241st Revision Received
10 Sep 2024Submission Checks Completed
10 Sep 2024Assigned to Editor
15 Oct 2024Reviewer(s) Assigned